D.J. St. Germain’s Corcept Therapeutics CORT Stock Holding History

D.J. St. Germain’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87K	Hold	1,000	–	–	﹤0.01%	401
2026 Q1	$40.3K	Hold	1,000	–	–	﹤0.01%	483
2025 Q4	$34.8K	Hold	1,000	–	–	﹤0.01%	511
2025 Q3	$83.1K	Hold	1,000	–	–	﹤0.01%	415
2025 Q2	$73.4K	Hold	1,000	–	–	﹤0.01%	418
2025 Q1	$114K	Hold	1,000	–	–	0.01%	315
2024 Q4	$50.4K	Hold	1,000	–	–	﹤0.01%	423
2024 Q3	$46.3K	Hold	1,000	–	–	﹤0.01%	395
2024 Q2	$32.5K	Hold	1,000	–	–	﹤0.01%	419
2024 Q1	$25.2K	Hold	1,000	–	–	﹤0.01%	457
2023 Q4	$32.5K	Hold	1,000	–	–	﹤0.01%	434
2023 Q3	$27.2K	Hold	1,000	–	–	﹤0.01%	428
2023 Q2	$22.3K	Buy	+1,000	New	+$23K	﹤0.01%	457

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.J. St. Germain's CORT Position: Q2 2026 in Review

D.J. St. Germain held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 1,000 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #401.

D.J. St. Germain first reported a position in CORT in Q2 2023 and has held it in 13 quarters since. The position peaked at $114K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

D.J. St. Germain held 1,000 shares of Corcept Therapeutics worth $87K as of Q2 2026.
D.J. St. Germain left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up ﹤0.01% of D.J. St. Germain's portfolio in Q2 2026, its #401 holding.
D.J. St. Germain first reported a position in Corcept Therapeutics in Q2 2023 and has held it in 13 quarters since.
D.J. St. Germain's Corcept Therapeutics position peaked at $114K in Q1 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on D.J. St. Germain's 13F filing for Q2 2026, filed 21 Jul 2026.